CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery — REFRESH II-AKI

Elective Cardiac Surgery Clinical Trial

Official title:
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)

Status Terminated

Clinical Trial Summary

Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03384875
Study type	Interventional
Source	CytoSorbents, Inc
Contact
Status	Terminated
Phase	N/A
Start date	April 19, 2018
Completion date	January 18, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02838524` - Acceptable Range of Inspiratory Effort During Mechanical Ventilation
Completed	`NCT02566525` - CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery	N/A
Completed	`NCT00879931` - Influence of Corticoids on Renal Function in Cardiac Surgery	Phase 2
Recruiting	`NCT05662501` - Pleiades Safety and Feasibility Study	N/A
Completed	`NCT02407873` - Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery	N/A
Not yet recruiting	`NCT01418521` - Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery	Phase 4
Completed	`NCT01748266` - Microcirculation of the Thenar Eminence	N/A